Quick Answer
Silence Therapeutics plc reported R&D Expense of $67.75 million for fiscal year 2025.
Silence Therapeutics plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $67.75M | -0.2% |
| 2024 | $67.88M | +19.2% |
| 2023 | $56.94M | +30.7% |
| 2022 | $43.55M | +41.6% |
| 2021 | $30.77M | +52.2% |
| 2020 | $20.21M | +51.5% |
| 2019 | $13.34M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.54M | +1.9% | +16.4% |
| June 30, 2025 | $17.65M | +27.9% | -15.2% |
| March 31, 2025 | $20.81M | +75.7% | +3.2% |
| September 30, 2024 | $20.16M | — | +46.1% |
| June 30, 2024 | $13.80M | — | +16.5% |
| March 31, 2024 | $11.85M | — | — |
- Silence Therapeutics plc showed a decrease of -0.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Silence Therapeutics plc’s r&d expense has grown by 408.0% (from $13.34 million to $67.75 million).
- The most recent figure is from Silence Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: